{"id":1807,"date":"2019-09-25T19:23:49","date_gmt":"2019-09-25T17:23:49","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1807"},"modified":"2024-01-11T15:28:43","modified_gmt":"2024-01-11T14:28:43","slug":"sarcoma","status":"publish","type":"page","link":"https:\/\/idibell.cat\/es\/investigacion\/area-de-cancer\/programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell\/sarcoma\/","title":{"rendered":"Sarcoma"},"content":{"rendered":"\n
El grupo de investigaci\u00f3n en sarcomas, liderado por \u00d2scar Martinez-Tirado, es un grupo multidisciplinar con los objetivos principales de identificar nuevos marcadores metast\u00e1ticos y profundizar en su papel biol\u00f3gico en sarcomas del desarrollo, e identificar nuevos objetivos terap\u00e9uticos y validar nuevos marcadores pron\u00f3sticos y predictivos en sarcomas, evaluando precl\u00ednicamente nuevos componentes para su tratamiento. Esta evaluaci\u00f3n precl\u00ednica incluye f\u00e1rmacos epigen\u00e9ticos, pro-apopt\u00f3ticos y bloqueantes del ciclo celular.<\/p>\n
Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Alava E, Dei Tos AP, del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krakorova DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez Pousa A, Martin Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schoffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, van de Sande M, van der Graaf W, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S, ESMO Guidelines C, E, G. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<\/strong>. Ann. Oncol. 2022;33(1):20-33. doi:10.1016\/j.annonc.2021.09.005.<\/p>\n Gounder MM, Razak AA, Somaiah N, Chawla S, Martin Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gr\u00f6schel S, Hatcher H, Duffaud F, Herr\u00e1ez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, G\u00f6tze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial<\/strong>. J. Clin. Oncol. 2022;40(22):2479-2490. doi:10.1200\/JCO.21.01829.<\/p>\n Archilla Ortega A, Domuro C, Martin Liberal J, Mu\u00f1oz P. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity<\/strong>. J. Exp. Clin. Cancer Res. 2022;41(1):62-62. doi:10.1186\/s13046-022-02264-x.<\/p>\n Pascual Pasto G, Castillo Ecija H, Unceta N, Aschero R, Resa Pares C, G\u00f3mez Caballero A, Vila Ubach M, Mu\u00f1oz Aznar O, Su\u00f1ol M, Burgue\u00f1o V, Gomez Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de \u00c1lava E, Tirado OM, Mora J, Carcaboso AM. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas<\/strong>. J Control Release. 2022;34281-92. doi:10.1016\/j.jconrel.2021.12.035.<\/p>\n Garc\u00eda Dom\u00ednguez DJ, Hajji N, L\u00f3pez Alemany R, S\u00e1nchez Molina S, Figuerola Bou E, Mor\u00f3n Civanto FJ, Rello Varona S, Andr\u00e9s Le\u00f3n E, Benito A, Keun HC, Mora J, Tirado \u00d3M, de \u00c1lava E, Hontecillas Prieto L. Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1<\/strong>. Oncogene. 2022;41(18):2638-2650. doi:10.1038\/s41388-022-02279-w.<\/p>\n\t\t\t\t\tProyectos seleccionados<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t FIS21126. TILS TREATMENT IN ADVANCED TUMORS WITH ALTERATIONS IN THE SWI\/SNF COMPLEX: THE TILTS STUDY<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 1081914,72. 2022-2025. PI: Mart\u00edn Liberal, Juan.<\/p>\n 20MAR001. Molecular analysis of the metastatic process in developmental tumors. Fundaci\u00f3 TV3<\/strong>. Budget: 300000. 2020-2023. PI: MARTINEZ TIRADO, OSCAR.<\/p>\n 19ACL231. ESTUDIO DE FASE 1B\/2 DE LY3200882 Y PEMBROLIZUMAB EN PACIENTES CON C\u00c1NCER AVANZADO<\/strong>. Budget: 267326,4. 2019- . PI: Mart\u00edn Liberal, Juan.<\/p>\n 2021-070-1. PROSPECTIVE COLLECTION OF DONOR TISSUE AND WHOLE BLOOD OR LEUKAPHERESIS PRODUCT FROM PATIENTS WITH SOLID TUMOURS TO ENABLE DEVELOPMENT OF METHODS FOR THE MANUFACTURING OF CLONAL NEOANTIGEN T CELL PRODUCTS (cNeT). ACHILLES THERAPEUTICS UK LIMITED<\/strong>. Budget: 220881,12. 2021- . PI: Mart\u00edn Liberal, Juan.<\/p>\n 20ACL101. A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. REGENERON PHARMACEUTICAL, INC<\/strong>. Budget: 203366,88. 2020- . PI: Mart\u00edn Liberal, Juan.<\/p>\n\t\t\t\t\tTransferencia de tecnolog\u00eda<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT064-EPH2A APTAMER AND USES THEREOF Sarcoma Resumen El grupo de investigaci\u00f3n en sarcomas, liderado por \u00d2scar Martinez-Tirado, es un grupo multidisciplinar con los objetivos principales de identificar nuevos marcadores metast\u00e1ticos y profundizar en su papel biol\u00f3gico en sarcomas del desarrollo, e identificar nuevos objetivos terap\u00e9uticos y validar nuevos marcadores pron\u00f3sticos y predictivos en sarcomas, evaluando precl\u00ednicamente nuevos componentes para su […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-10 02:33:36","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/1807"}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=1807"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/1807\/revisions"}],"predecessor-version":[{"id":23688,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/1807\/revisions\/23688"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=1807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nIP: Oscar Mart\u00ednez tirado
\nEP19382451\nLicense: EPH2A APTAMER AND USES THEREOF
\nPI: Dr. \u00d3scar Mart\u00ednez-Tirado\nSpin-off: Aptadel Therapeutics
\nPI: Dr. \u00d3scar Mart\u00ednez-Tirado\n\t\t\t\t\tM\u00e1s informaci\u00f3n<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tDesarrollo de un nuevo modelo ortot\u00f3pico para estudiar la met\u00e1stasis del sarcoma
\nDescripci\u00f3n del metiloma del sarcoma de Ewing.\n\t\t\t\t\n\n\t\tMartinez Tirado, Oscar\n\t<\/h4>\n
\n\t\t\n\t\tomartinez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tInvestigadores principales\n\t<\/h2>\n\t\t\t\t\n
\n\t\tMartinez Tirado, Oscar\n\t<\/h4>\n
\n\t\t\n\t\tomartinez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tGarc\u00eda del Muro, Solans Xavier\n\t<\/h4>\n
\n\t\t\n\t\tgarciadelmuro@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tENLACES RELACIONADOS\n\t<\/h4>\n
\n\t\t\n\t\tFacebook\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@SRGIDIBELL\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@omt2007\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tEquipo\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tJefes\/as de grupo\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadores\/as principales\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadores\/as cl\u00ednicos\/as\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadores\/as postdoctorales\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadores\/as predoctorales\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSoporte cient\u00edfico\t\t\t\t<\/a>\n\t\t\t\t\t\tJefes\/as de grupo\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n
\n\t\tNoticias relacionadas\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL y la Universidad de Iowa desarrollan una nueva mol\u00e9cula para el tratamiento dirigido contra el c\u00e0ncer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/05\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL recibe 1,2 millones de euros en ayudas para impulsar la investigaci\u00f3n cient\u00edfica y su transferencia<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/01\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa inhibici\u00f3n farmacol\u00f3gica de una prote\u00edna reduce las met\u00e1stasis en modelos in vivo e in vitro de Sarcoma de Ewing<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t01\/04\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa spin-off salida del IDIBELL Aptadel seleccionada para formar parte de BCN Health Booster<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t26\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn nuevo algoritmo clasifica tipos de sarcoma<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t02\/02\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tAptadel, nueva spinoff del IDIBELL<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/01\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl grupo de investigaci\u00f3n en sarcoma del IDIBELL recibir\u00e1 una de las nuevas ayudas AECC Innova<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/09\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIdentifican una prote\u00edna determinante para la progresi\u00f3n tumoral y la met\u00e1stasis del c\u00e1ncer infantil Rabdomiosarcoma<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/01\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl IDIBELL y la Fundaci\u00f3n Alba P\u00e9rez hacen un nuevo paso adelante para desarrollar un tratamiento para el sarcoma de Ewing<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/12\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa Marat\u00f3 impulsa 43 proyectos sobre el c\u00e1ncer en la inversi\u00f3n anual en investigaci\u00f3n m\u00e1s grande de su historia<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t31\/10\/2019\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"